India’s regulator of drug pricing, the National Pharmaceutical Pricing Authority, has issued orders fixing the maximum price that patients can be charged for coronary stents. Stents are currently included in the country’s national list of essential medicines.
While the government expects the price cap to benefit patients, US-based medtech industry association AdvaMed said its member companies were...






